| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3334994 | Transfusion and Apheresis Science | 2014 | 8 Pages |
Abstract
This study assessed the cost-effectiveness of Octaplas™ versus fresh frozen plasma (FFP) in patients receiving plasma transfusions in the United States (US). Acute and long-term complications of plasma transfusions were modelled in a decision tree followed by a Markov model, using a healthcare payer perspective. Over a lifetime time horizon, patients receiving Octaplas™ accumulate slightly more life years (0.00613 [95% uncertainty interval (95%UI): 0.00166–0.01561]) and quality-adjusted life years (QALY) (0.023 [95%UI: 0.012–0.044]) at lower cost compared with those treated with FFP. Octaplas™ demonstrated to be the dominant treatment option over FFP (95%UI: Dominant–US$ 15,764/QALY).
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Eline L. Huisman, Shamika U. de Silva, Maria A. de Peuter,